

Clatterbridge Road Bebington Wirral CH63 4JY

Tel: 0151 556 5000 Web: www.clatterbridgecc.nhs.uk

Date: 18 August 2020

Re: Freedom of Information Request

Ref: 173-2020

Thank you for your email dated the 3rd August 2020, requesting information in relation to atopic dermatitis.

The information that you require is as follows:

We are conducting a piece of research into atopic dermatitis treatments. Under the Freedom of Information Act 2000 we would like to request the information contained in the attached document.

I can confirm that our Trust does not hold any information in this regard. As we are a tertiary specialist cancer treatment centre we do not treat atopic dermatitis and have not treated patients with any of the drugs listed within your request (see Appendix 1). Therefore, the information you have requested is not applicable to our Trust in this instance.

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

https://www.surveymonkey.co.uk/r/H39RFMM

Appendix 1

1. How many patients were treated within your Trust with the following drugs within the specified time periods?

Drug	Number of patients treated between 01 February 2017 and 31 July 2018	Number of patients treated between 01 August 2018 and 31 January 2020
Apremilast		
Adalimumab		
Dupilumab		
Etanercept		
Infliximab		
Secukinumab		
Ustekinumab		

2. How many patients were treated within your Trust for <u>atopic dermatitis</u> within the specified time periods?

Number of patients treated for atopic	Number of patients treated for atopic
dermatitis between 01 February 2017 and 31	dermatitis between 01 August 2018 and 31
July 2018	January 2020

3. How many patients were treated within your Trust with the following drugs for <u>atopic</u> <u>dermatitis</u> within the specified time periods?

Drug	Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
Apremilast		
Adalimumab		
Dupilumab		
Etanercept		
Infliximab		
Secukinumab		
Ustekinumab		

4. Please specify how patients treated with the following drugs are coded (OPCS code) within your trust:

Drug	OPCS code (e.g. X385 subcutaneous immunotherapy)
Apremilast	
Adalimumab	
Dupilumab	
Etanercept	
Infliximab	
Secukinumab	
Ustekinumab	

5.	Please provide the number of patients treated in the homecare setting for <u>atopic dermatiti</u>
	vithin the specified time periods:

Number of patients treated in the homecare	Number of patients treated in the homecare
setting for atopic dermatitis between 01	setting for atopic dermatitis between 01
February 2017 and 31 July 2018	August 2018 and 31 January 2020

6. How many of your Trust's <u>homecare patients</u> were treated with the following drugs for <u>atopic dermatitis</u> within the specified time periods?

Drug	Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
Apremilast		
Adalimumab		
Dupilumab		
Etanercept		
Infliximab		
Secukinumab		
Ustekinumab		